Independent register of U.S. FDA drug recalls · updated Oct 14, 2026
RxRecalls Get alerts

Class II drug recalls - moderate risk

Class II means the product may cause temporary or medically reversible harm, and serious harm is unlikely. It is by far the largest recall class - most potency, dissolution and labeling problems land here.

14,543 recalls, newest first.

Class II · Moderate risk

CVS Health

CGMP Deviations: products manufactured under conditions that could impact its product quality.

Terminated cGMP deviation Product Quest Manufacturing LLC D-0032-2019
Class II · Moderate risk

CVS Health

CGMP Deviations: products manufactured under conditions that could impact its product quality.

Terminated cGMP deviation Product Quest Manufacturing LLC D-0031-2019
Class II · Moderate risk

CVS Health

CGMP Deviations: products manufactured under conditions that could impact its product quality.

Terminated cGMP deviation Product Quest Manufacturing LLC D-0030-2019
Class II · Moderate risk

CareOne

CGMP Deviations: products manufactured under conditions that could impact its product quality.

Terminated cGMP deviation Product Quest Manufacturing LLC D-0029-2019
Class II · Moderate risk

Lidocaine 2.5% and Prilocaine Cream

Failed Impurities/Degredation Specifications: Out of Specification results for an unknown impurity was found during routine stability testing at 12 months.

Terminated Impurity / degradation Akorn, Inc. NDC 50383-667-30 D-1046-2018
Class II · Moderate risk

Valsartan 320 mg tablets

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Terminated Nitrosamine impurity Bryant Ranch Prepack Inc. NDC 71335-0567-2 D-1029-2018
Class II · Moderate risk

Valsartan 320 mg tablets

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Terminated Nitrosamine impurity Bryant Ranch Prepack Inc. NDC 63629-6905-1 D-1028-2018
Class II · Moderate risk

Valsartan 80 mg tablets

CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.

Terminated Nitrosamine impurity Bryant Ranch Prepack Inc. NDC 63629-6922-2 D-1027-2018
Class II · Moderate risk

Valsartan tablets 160 mg

Carcinogen impurity detected in API used to manufacture drug product.

Terminated Nitrosamine impurity H J Harkins Company Inc dba Pharma Pac NDC 43547-0369-09 D-1022-2018

Recalls by year